MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Eli Lilly and Co.

Geschlossen

BrancheGesundheitswesen

788.37 -3.8

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

787

Max

817.16

Schlüsselkennzahlen

By Trading Economics

Einkommen

7.8B

8.8B

Verkäufe

2.1B

14B

KGV

Branchendurchschnitt

70.41

63.778

EPS

5.32

Dividendenrendite

0.73

Gewinnspanne

65.172

Angestellte

47,000

EBITDA

1.2B

6.1B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+27.58% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.73%

2.39%

Nächstes Ergebnis

1. Mai 2025

Nächstes Ex-Dividendendatum

14. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-43B

742B

Vorheriger Eröffnungskurs

792.17

Vorheriger Schlusskurs

788.37

Nachrichtenstimmung

By Acuity

16%

84%

27 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Eli Lilly and Co. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Apr. 2025, 23:15 UTC

Wichtige Markttreiber

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2. Apr. 2025, 16:53 UTC

Top News

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

1. Apr. 2025, 22:31 UTC

Top News

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1. Apr. 2025, 21:47 UTC

Top News

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

19. März 2025, 15:54 UTC

Top News

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

14. März 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

28. Feb. 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26. Feb. 2025, 15:14 UTC

Top News

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

26. Feb. 2025, 14:30 UTC

Top News

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

10. Feb. 2025, 12:00 UTC

Top News

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7. Feb. 2025, 10:30 UTC

Top News

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6. Feb. 2025, 16:16 UTC

Top News
Ergebnisse

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6. Feb. 2025, 14:56 UTC

Ergebnisse

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

6. Feb. 2025, 14:32 UTC

Market Talk
Ergebnisse

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

6. Feb. 2025, 13:18 UTC

Top News
Ergebnisse

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

6. Feb. 2025, 12:24 UTC

Ergebnisse

Eli Lilly Stock Rises After Earnings Beat, Upbeat Guidance -- Barrons.com

6. Feb. 2025, 12:01 UTC

Ergebnisse

Eli Lilly Stock Rises After Earnings Beat -- Barrons.com

6. Feb. 2025, 11:49 UTC

Ergebnisse

Eli Lilly Sees Producing at Least 1.6 Times Amount of Salable Incretin Doses in 1st Half of 2025 Vs 1st Half of 2024 >LLY

6. Feb. 2025, 11:48 UTC

Ergebnisse

Eli Lilly 4Q U.S. Zepbound Revenue $1.91B >LLY

6. Feb. 2025, 11:47 UTC

Ergebnisse

Eli Lilly 4Q Worldwide Mounjaro Revenue Rose 60% to $3.53B >LLY

6. Feb. 2025, 11:46 UTC

Ergebnisse

Eli Lilly 4Q Gross Margin 82.2% >LLY

6. Feb. 2025, 11:45 UTC

Ergebnisse

Eli Lilly 4Q Trulicity Rev $1.25B >LLY

6. Feb. 2025, 11:45 UTC

Ergebnisse

Eli Lilly Sees FY Adj EPS $22.50-Adj EPS $24.00 >LLY

6. Feb. 2025, 11:45 UTC

Ergebnisse

Eli Lilly 4Q Humalog Rev $619.9M >LLY

6. Feb. 2025, 11:45 UTC

Ergebnisse

Eli Lilly Sees FY Rev $58B-$61B >LLY

6. Feb. 2025, 11:45 UTC

Ergebnisse

Eli Lilly 4Q Net $4.41B >LLY

6. Feb. 2025, 11:45 UTC

Ergebnisse

Eli Lilly 4Q EPS $4.88 >LLY

6. Feb. 2025, 11:45 UTC

Ergebnisse

Eli Lilly Sees FY EPS $22.05-EPS $23.55 >LLY

6. Feb. 2025, 11:45 UTC

Ergebnisse

Eli Lilly 4Q Jardiance Rev $1.2B >LLY

6. Feb. 2025, 11:45 UTC

Ergebnisse

Eli Lilly 4Q Rev $13.53B >LLY

Peer-Vergleich

Kursveränderung

Eli Lilly and Co. Prognose

Kursziel

By TipRanks

27.58% Vorteil

12-Monats-Prognose

Durchschnitt 1,043.87 USD  27.58%

Hoch 1,190 USD

Tief 900 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Eli Lilly and Co. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

18

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

797 / 825.32Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

27 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.